Last reviewed · How we verify
IPN10200
IPN10200 is a somatostatin receptor agonist that binds to somatostatin receptors to inhibit hormone secretion and tumor growth.
IPN10200 is a somatostatin receptor agonist that binds to somatostatin receptors to inhibit hormone secretion and tumor growth. Used for Neuroendocrine tumors, Acromegaly.
At a glance
| Generic name | IPN10200 |
|---|---|
| Sponsor | Ipsen |
| Drug class | Somatostatin receptor agonist |
| Target | Somatostatin receptors (SSTR) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IPN10200 acts as a somatostatin analog, activating somatostatin receptors on neuroendocrine tumor cells and hormone-secreting cells. This activation suppresses the release of excess hormones and inhibits tumor cell proliferation. The drug is designed to treat neuroendocrine tumors and hormone-related disorders by modulating somatostatin signaling pathways.
Approved indications
- Neuroendocrine tumors
- Acromegaly
Common side effects
- Gastrointestinal disturbances
- Hyperglycemia
- Injection site reactions
- Fatigue
Key clinical trials
- A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (PHASE3)
- A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (PHASE3)
- A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults (PHASE2)
- A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. (PHASE1, PHASE2)
- A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults (PHASE2)
- A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPN10200 CI brief — competitive landscape report
- IPN10200 updates RSS · CI watch RSS
- Ipsen portfolio CI